The FDA has approved Olumiant (baricitinib), a once-daily pill, for treating severe alopecia areata (AA) in pediatric patients aged 12 and older. This approval is based on positive results from the BRAVE-AA-PEDS Phase 3 study, showing significant scalp hair regrowth and improvements in eyebrows and eyelashes after 36 weeks of treatment. Severe AA causes extensive hair loss, especially impactful during adolescence, and this new approval expands treatment options for young patients who previously had limited choices. Olumiant is already approved for adults with severe AA and rheumatoid arthritis, and this pediatric approval marks a major advancement in care for immune-mediated diseases.
Eli Lilly's recent FDA approval for Olumiant in pediatric alopecia areata patients highlights the company's ongoing innovation in health treatments. On Pluang, Eli Lilly (LLY) shares are priced at USD 1,183.55 with a slight 0.03% decrease as of Sep 26, 2026 04:21 WIB. The stock shows a market cap of $1.05 trillion and a dividend yield of 0.59%, with a typical hold time of 93 days and a balanced order activity leaning slightly towards selling at 55%.
Novo Nordisk revealed a strategy to boost growth beyond its top obesity drugs Wegovy and Ozempic, facing patent expirations in the early 2030s. Despite promising a pipeline of new drugs, investors remain skeptical as Eli Lilly gains market share, esp...
The US FDA has approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes, offering a new alternative to daily insulin injections. Onswik, used alongside diet and exercise, can reduce injection frequency by over 300 times...
Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and raised its full-year revenue guidance. Pfizer showed modest growth with a 5.4% revenue increase in Q1 2026, focusing on oncology and obesity ...
Viking Therapeutics surged 26.5% after releasing positive topline results from its GLP-1/GIP agonist VK2735 maintenance dosing study in adults with obesity. The data suggest multiple effective maintenance dosing schedules, potentially improving patie...
Ken Langone, co-founder of Home Depot, stated that Eli Lilly stock could reach $2,000 within the next 3 to 4 years, challenging the long-term success of his Home Depot investment. Eli Lilly has shown strong growth, up over 54% in the past year despit...
